Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany

Table 2 Postoperative patient characteristics

Kind of operation	129 patients	% of the 129	Number/percent with neoadjuvant chemotherapy
Subtotal resection	40	31%	4 of 40/10%
Gastrectomy	57	44%	21 of 57/37%
Expanded gastrectomy	11	9%	6 of 11/55%
Transhiatal oesophagus resection (Merendino)	3	2%	1 of 3/33%
Transthoracal oesophagus resection (with gastric endo-sleeve)	18	14%	14 of 18/78%
LAD
D1 (intraoperative M+, PC or no R0 possible)	11	8.5%
D2	118	91.5%
T
T0	7	5.4%	(ypT0 = 7)
T1	8	6.2%	(ypT1N0 = 5, pT1/N1 = 3)
T2	25	19.4%	(ypT2 = 12, pT2/N+ = 13)
T3	56	43.4%	(ypT3 = 18, pT3 = 37)
T4	33	25.6%	(ypT4 = 3, pT4 = 30)
N
N0	37	29%
N+	92	71%
M
M0	112	87%
M1	17	13%
Signet-ring cells
Yes	28	22%
No	101	78%
UICC
UICC IA	12	9.3%
UICC IB	7	5.4%
UICC IIA	21	16.3%
UICC IIB	26	20.2%
UICC IIIA	17	13.2%
UICC IIIB	14	10.9%
UICC IIIC	16	12.4%
UICC IV	16	12.4%

LAD: Lymph node dissection; UICC: Union internationale contre le cancer; T: Tumour size; N+: Positive lymph nodes; N0: Negative lymph nodes; M+: Distant metastases; M0: No distant metastases; PC: Peritoneal carcinosis.